Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ariela Noy

Showing results (21-30 of 138) with videos related to

Pageof 14
Sort By:
Leukemia & Lymphoma|November 22, 2017
Combination antiretroviral therapy accelerates immune recovery in patients with HIV-related lymphoma treated with EPOCH: a comparison within one prospective trial AMC034Carlyn Rose C Tan, Stefan K Barta, Jeannette Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2004
Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study TeamAriela Noy, David T Scadden, Jeannette Lee, et al.
Infectious Agents and Cancer|October 30, 2025
Methylation-specific qPCR for the EBV C promoter to quantify EBV methylationLogan George, Paul G Rubinstein, Jennifer Petr, et al.
Blood Advances|November 18, 2022
Predictors of survival in patients with MALT lymphoma: a retrospective, case-control studyShunan Qi, Xin Liu, Ariela Noy, et al.
Clinical Nuclear Medicine|April 30, 2020
Rosai-Dorfman Disease-Utility of 18F-FDG PET/CT for Initial Evaluation and Follow-upSonia Mahajan, Reiko Nakajima, Mariko Yabe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2005
Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphomaHeiko Schöder, Ariela Noy, Mithat Gönen, et al.
Blood|May 10, 2015
AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphomaAriela Noy, Jeannette Y Lee, Ethel Cesarman, et al.
Blood|August 19, 2004
Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin diseaseDavid J Straus, Carol S Portlock, Jing Qin, et al.
Cancers|January 28, 2026
Romiplostim for Prevention of Severe Chemotherapy-Induced Thrombocytopenia in Lymphoma Patients-Phase I StudyErel Joffe, Zachary Epstein-Peterson, Lorenzo Falchi, et al.
Leukemia & Lymphoma|July 16, 2005
R-CHOP-14 in patients with diffuse large B-cell lymphoma: feasibility and preliminary efficacyJeffrey L Halaas, Craig H Moskowitz, Steven Horwitz, et al.
Pageof 14

Showing results (21-30 of 138) with videos related to

Sort By:
Pageof 14
Leukemia & Lymphoma|November 22, 2017
Combination antiretroviral therapy accelerates immune recovery in patients with HIV-related lymphoma treated with EPOCH: a comparison within one prospective trial AMC034Carlyn Rose C Tan, Stefan K Barta, Jeannette Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2004
Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study TeamAriela Noy, David T Scadden, Jeannette Lee, et al.
Infectious Agents and Cancer|October 30, 2025
Methylation-specific qPCR for the EBV C promoter to quantify EBV methylationLogan George, Paul G Rubinstein, Jennifer Petr, et al.
Blood Advances|November 18, 2022
Predictors of survival in patients with MALT lymphoma: a retrospective, case-control studyShunan Qi, Xin Liu, Ariela Noy, et al.
Clinical Nuclear Medicine|April 30, 2020
Rosai-Dorfman Disease-Utility of 18F-FDG PET/CT for Initial Evaluation and Follow-upSonia Mahajan, Reiko Nakajima, Mariko Yabe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2005
Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphomaHeiko Schöder, Ariela Noy, Mithat Gönen, et al.
Blood|May 10, 2015
AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphomaAriela Noy, Jeannette Y Lee, Ethel Cesarman, et al.
Blood|August 19, 2004
Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin diseaseDavid J Straus, Carol S Portlock, Jing Qin, et al.
Cancers|January 28, 2026
Romiplostim for Prevention of Severe Chemotherapy-Induced Thrombocytopenia in Lymphoma Patients-Phase I StudyErel Joffe, Zachary Epstein-Peterson, Lorenzo Falchi, et al.
Leukemia & Lymphoma|July 16, 2005
R-CHOP-14 in patients with diffuse large B-cell lymphoma: feasibility and preliminary efficacyJeffrey L Halaas, Craig H Moskowitz, Steven Horwitz, et al.
Pageof 14